Valerie Durkalski-Mauldin
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Research Design | 4 | 2019 | 729 | 1.360 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 931 | 1.100 |
Why?
|
| Sphincter of Oddi Dysfunction | 3 | 2017 | 48 | 1.040 |
Why?
|
| Abdominal Pain | 3 | 2017 | 97 | 1.010 |
Why?
|
| Sphincterotomy, Endoscopic | 3 | 2022 | 79 | 0.770 |
Why?
|
| Adaptive Clinical Trials as Topic | 1 | 2019 | 2 | 0.670 |
Why?
|
| Bayes Theorem | 2 | 2019 | 307 | 0.660 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2022 | 348 | 0.640 |
Why?
|
| Emergency Medical Services | 2 | 2019 | 225 | 0.620 |
Why?
|
| Sphincter of Oddi | 1 | 2017 | 51 | 0.570 |
Why?
|
| Cholecystectomy | 1 | 2017 | 79 | 0.560 |
Why?
|
| Liver Failure, Acute | 3 | 2022 | 49 | 0.540 |
Why?
|
| Data Interpretation, Statistical | 3 | 2019 | 329 | 0.520 |
Why?
|
| Algorithms | 2 | 2019 | 1196 | 0.500 |
Why?
|
| Pain, Postoperative | 1 | 2017 | 214 | 0.490 |
Why?
|
| Status Epilepticus | 2 | 2015 | 74 | 0.480 |
Why?
|
| Anticonvulsants | 2 | 2015 | 223 | 0.450 |
Why?
|
| Matched-Pair Analysis | 2 | 2003 | 25 | 0.440 |
Why?
|
| Stroke | 3 | 2019 | 2163 | 0.410 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 186 | 0.390 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 84 | 0.380 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2023 | 87 | 0.370 |
Why?
|
| Information Management | 1 | 2010 | 23 | 0.350 |
Why?
|
| Epidemiologic Research Design | 1 | 2009 | 5 | 0.330 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2009 | 14 | 0.330 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2021 | 131 | 0.320 |
Why?
|
| Endpoint Determination | 1 | 2009 | 82 | 0.320 |
Why?
|
| Disability Evaluation | 1 | 2010 | 298 | 0.320 |
Why?
|
| Biometry | 1 | 2009 | 72 | 0.310 |
Why?
|
| Patient Selection | 1 | 2012 | 592 | 0.310 |
Why?
|
| Liver Function Tests | 2 | 2019 | 114 | 0.310 |
Why?
|
| Hyperglycemia | 2 | 2019 | 158 | 0.300 |
Why?
|
| Humans | 27 | 2023 | 68618 | 0.290 |
Why?
|
| Internet | 1 | 2010 | 390 | 0.280 |
Why?
|
| Depressive Disorder, Major | 1 | 2010 | 439 | 0.250 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2010 | 413 | 0.250 |
Why?
|
| Sphincterotomy | 1 | 2022 | 2 | 0.220 |
Why?
|
| Cluster Analysis | 1 | 2003 | 219 | 0.210 |
Why?
|
| Pancreas | 2 | 2022 | 225 | 0.210 |
Why?
|
| Statistics as Topic | 1 | 2003 | 219 | 0.210 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 45 | 0.190 |
Why?
|
| Adult | 12 | 2023 | 21403 | 0.190 |
Why?
|
| Outpatients | 1 | 2021 | 127 | 0.190 |
Why?
|
| Pancreatitis, Chronic | 1 | 2022 | 168 | 0.190 |
Why?
|
| Primary Health Care | 3 | 2023 | 703 | 0.180 |
Why?
|
| Treatment Outcome | 7 | 2021 | 7029 | 0.180 |
Why?
|
| Hepatitis C Antibodies | 1 | 2019 | 19 | 0.170 |
Why?
|
| Hepcidins | 1 | 2019 | 6 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2021 | 328 | 0.170 |
Why?
|
| Nitroglycerin | 1 | 2019 | 20 | 0.170 |
Why?
|
| Ambulances | 1 | 2019 | 27 | 0.160 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 191 | 0.160 |
Why?
|
| Cerebral Hemorrhage | 1 | 2020 | 198 | 0.160 |
Why?
|
| Liver Transplantation | 1 | 2022 | 400 | 0.160 |
Why?
|
| Endosonography | 1 | 2019 | 177 | 0.160 |
Why?
|
| Computer Simulation | 2 | 2017 | 706 | 0.160 |
Why?
|
| Sex Characteristics | 1 | 2020 | 295 | 0.150 |
Why?
|
| Hepatitis C | 1 | 2019 | 114 | 0.150 |
Why?
|
| Disease Progression | 1 | 2021 | 1038 | 0.150 |
Why?
|
| Pancreatitis | 1 | 2019 | 279 | 0.140 |
Why?
|
| Iron | 1 | 2019 | 197 | 0.140 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2016 | 9 | 0.140 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2016 | 9 | 0.140 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 362 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 498 | 0.140 |
Why?
|
| Insulin | 1 | 2019 | 619 | 0.130 |
Why?
|
| Liver Diseases | 1 | 2018 | 193 | 0.130 |
Why?
|
| Allied Health Personnel | 2 | 2015 | 37 | 0.130 |
Why?
|
| Lorazepam | 1 | 2015 | 54 | 0.120 |
Why?
|
| Midazolam | 1 | 2015 | 46 | 0.120 |
Why?
|
| Female | 12 | 2022 | 38074 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2018 | 374 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2020 | 1451 | 0.120 |
Why?
|
| Middle Aged | 9 | 2022 | 21147 | 0.110 |
Why?
|
| Male | 12 | 2022 | 37321 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 1851 | 0.100 |
Why?
|
| Aspartate Aminotransferases | 2 | 2023 | 87 | 0.100 |
Why?
|
| Investigational New Drug Application | 1 | 2011 | 1 | 0.100 |
Why?
|
| Immunization, Passive | 2 | 2021 | 24 | 0.100 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 53 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2023 | 7277 | 0.100 |
Why?
|
| Placebos | 1 | 2011 | 195 | 0.100 |
Why?
|
| Hypertension | 1 | 2020 | 1535 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2016 | 1342 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 131 | 0.090 |
Why?
|
| Time Factors | 1 | 2019 | 4655 | 0.090 |
Why?
|
| Emergency Medicine | 1 | 2011 | 88 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2022 | 2358 | 0.090 |
Why?
|
| Infusions, Intravenous | 2 | 2021 | 334 | 0.090 |
Why?
|
| Internationality | 2 | 2020 | 74 | 0.090 |
Why?
|
| Acetaminophen | 2 | 2021 | 111 | 0.080 |
Why?
|
| United States | 3 | 2019 | 7367 | 0.080 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 301 | 0.080 |
Why?
|
| Recurrence | 2 | 2022 | 948 | 0.080 |
Why?
|
| Aged | 5 | 2021 | 14862 | 0.080 |
Why?
|
| Young Adult | 3 | 2021 | 5717 | 0.060 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2003 | 51 | 0.050 |
Why?
|
| Monte Carlo Method | 1 | 2003 | 124 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2003 | 242 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 40 | 0.050 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 40 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 8912 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2003 | 137 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 2800 | 0.050 |
Why?
|
| Alberta | 1 | 2022 | 15 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 67 | 0.050 |
Why?
|
| Propensity Score | 1 | 2022 | 117 | 0.050 |
Why?
|
| Thrombelastography | 1 | 2021 | 19 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 46 | 0.050 |
Why?
|
| Acute Disease | 1 | 2022 | 658 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 216 | 0.050 |
Why?
|
| Fibrosis | 1 | 2023 | 371 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 249 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2021 | 137 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 110 | 0.050 |
Why?
|
| Risk Factors | 2 | 2021 | 5731 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2022 | 546 | 0.040 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2019 | 20 | 0.040 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 87 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 848 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 540 | 0.040 |
Why?
|
| Hypoglycemia | 1 | 2019 | 72 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1753 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2019 | 291 | 0.040 |
Why?
|
| Logistic Models | 1 | 2022 | 1420 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2018 | 118 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 296 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2019 | 377 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 978 | 0.030 |
Why?
|
| Liver | 1 | 2021 | 1118 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 711 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 44 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 1046 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 89 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2015 | 172 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2019 | 665 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1619 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 2791 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 4848 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2550 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 3705 | 0.020 |
Why?
|
| Infant | 1 | 2015 | 2891 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 3187 | 0.020 |
Why?
|
| Child | 1 | 2015 | 6405 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 20881 | 0.010 |
Why?
|